Product logins

Find logins to all Clarivate products below.


Clarivate Epidemiology’s coverage of venous thromboembolism (VTE) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed incidence of VTE for each country, as well as annualized event counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan; we use 10 years for the rest of the countries.

Clarivate Epidemiology’s VTE forecast will answer the following questions:

  • Of all diagnosed VTE events, how many in each country are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of VTE over the forecast period?
  • How will improvements in healthcare access and diagnostic technology affect the epidemiology of VTE in the low-income countries over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology forecasts eight VTE patient populations as follows:

  • Diagnosed VTE events.
  • Diagnosed DVT events.
  • Diagnosed PE events.
  • Diagnosed DVT events by drug treatment.
  • Diagnosed PE events by drug treatment.
  • Diagnosed VTE events by etiology.
  • Diagnosed VTE events by cancer association.
  • Diagnosed VTE events by recurrence.

Note: Coverage may vary by country and region.

Related Market Assessment Reports

Report
Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer
China’s breast cancer market continues to evolve rapidly, driven by rising incidence and expanding systemic treatment options. Several new and emerging therapies are expected to gain approval for…
Report
Chronic Obstructive Pulmonary Disease – Unmet Need – Unmet Need – Severe to Very Severe Chronic Obstructive Pulmonary Disease (US EU)
The severe to very severe chronic COPD market is crowded, with numerous LAMA, LABA/ICS, LABA/LAMA, and triple LABA/LAMA/ICS inhalers competing for use. Although dual and triple longacting…
Report
Diabetic Macular Edema / Diabetic Retinopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Diabetic Macular Edema (US)
Diabetic macular edema (DME) is a serious complication of diabetic retinopathy caused by persistently elevated blood glucose levels. Without timely treatment, DME can progress to significant vision…
Report
Multiple System Atrophy – Unmet Need – Multiple System Atrophy (US/EU) – Unmet Need – Multiple System Atrophy (US/EU)
Multiple system atrophy (MSA) is a rare, rapidly progressing neurodegenerative synucleinopathy that disrupts movement, balance, and autonomic function. Current management comprises only symptomatic…
Report
Sarcoidosis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Sarcoidosis (US)
Sarcoidosis is a multisystem inflammatory disorder marked by granuloma formation, most often affecting the lungs, lymph nodes, skin, eyes, and heart. Corticosteroids such as prednisone are the…